Face masks supplier United Sewing Automation Inc (USA) revealed on Wednesday that its ASTM Rated Level 3 Disposable PPE face masks produced at its new automated manufacturing facility in Mount Airy, NC is in compliance with the Berry Amendment and qualify for Department of Defense contracts following an extensive testing in an ISO 17025 accredited laboratory in the fight against COVID-9.
The US FDA, which oversees the sale and marketing of all surgical masks, requires that United Sewing must demonstrate mask performance in several critical areas: Bacterial Filtration, Particulate Filtration, Liquid Barrier Protection, Breathability and Flammability.
Based on the FDA requirement, the company's masks passed bacterial filtration efficiency of 99.62%, particulate filtration efficiency of 99.76%, fluid resistance at 160 mmHg, Class 1 flammability of 16CFR 1610, differential pressure at 4.8mm as well as achieved non-cytotoxic and non-irritating biocompatibility.
According to the company, the masks are made from high-quality, USA-sourced materials as well as feature a three-ply design with a built-in adjustable nose bridge and ear loops made of nylon and Spandex, providing a better fit than traditional disposable masks.
FDA grants priority review to Takeda's zasocitinib application for plaque psoriasis
Armata Pharmaceuticals announces receipt of FDA Breakthrough Therapy Designation for AP-SA02
GSK reports positive Jideytro data supporting potential first-line lung cancer use
Eloxx Pharmaceuticals commences Phase 2b study of exaluren
Meant Health announces expansion of telehealth access for FDA-approved GLP-1 prescriptions
US FDA grants orphan drug designation for Lundbeck's asedebart
Renova Pharmaceuticals launches first three US generic products
FDA grants Priority Review to Genentech's Enspryng for MOGAD
CordenPharma increases aseptic fill-finish capacity
Biophytis expands BIO101 obesity study to assess weight regain
THX Pharma secures European patent for Batten-1 in juvenile Batten disease
Etcamah–CDK4/6 inhibitor combination approved in US for ESR1-mutated HR-positive breast cancer
Guardant Health wins FDA approval for Guardant360 CDx in advanced breast cancer